Imbruvica Archives -

ASCO21: AZ seeks to supplant Imbruvica in CLL with new Calquence data

Phil Taylor AbbVie, AstraZeneca, BeiGene, Brukinsa, Calquence, chronic lymphocytic leukaemia, Haematology, Imbruvica, Johnson & Johnson, Oncology 0 Comment

AstraZeneca has thrown down the gauntlet to AbbVie and Johnson & Johnson with new data for Calquence in

ASCO21: AZ seeks to supplant Imbruvica in CLL with new Calquence data

https://pharmaphorum.com/news/asco21-az-seeks-to-supplant-imbruvica-in-cll-with-new-calquence-data/

News/ News/ Oncology

AZ says Calquence is a safer drug than Imbruvica

Phil Taylor AbbVie, AstraZeneca, BTK inhibitor, Calquence, chronic lymphocytic leukaemia, Imbruvica, Johnson & Johnson, Oncology 0 Comment

AstraZeneca’s fast-growing BTK inhibitor Calquence is already challenging class leader Imbruvica from Johnson & Johnson/AbbVie in the treatment

AZ says Calquence is a safer drug than Imbruvica

https://pharmaphorum.com/news/az-says-calquence-is-a-safer-drug-than-imbruvica/

News/ News/ Oncology

ASH: Lilly builds case for its BTK drug LOXO-305 in lymphoma

Phil Taylor AbbVie, American Society of Haematology, BTK inhibitor, Eli Lilly, Imbruvica, Johnson & Johnson, non-Hodgkin lymphoma 0 Comment

Eli Lilly’s buyout of Loxo Oncology last year has already yielded one approved drug, and it now has

ASH: Lilly builds case for its BTK drug LOXO-305 in lymphoma

https://pharmaphorum.com/news/ash-lilly-builds-case-for-its-btk-drug-loxo-305-in-lymphoma/

Market Access/ News/ News/ News/ Oncology

AbbVie, J&J embed Imbruvica deeper in CLL therapy with new approval

Phil Taylor AbbVie, chronic lymphocytic leukaemia, Imbruvica, Johnson & Johnson, Oncology 0 Comment

AbbVie and Johnson & Johnson’s Imbruvica is already a mainstay of chronic lymphocytic leukaemia (CLL) therapy, but can

AbbVie, J&J embed Imbruvica deeper in CLL therapy with new approval

https://pharmaphorum.com/news/abbvie-jj-embed-imbruvica-deeper-in-cll-therapy-with-new-approval/

News/ News/ News/ Oncology/ R&D

BeiGene’s Brukinsa fails to beat AbbVie/J&J’s Ibrutinib in WM

Richard Staines AbbVie, BeiGene, Brukinsa, Imbruvica, Johnson & Johnson 0 Comment

BeiGene’s Brukinsa (zanubrutinib) has failed to outperform its class rival from Johnson & Johnson/AbbVie in the rare white

BeiGene’s Brukinsa fails to beat AbbVie/J&J’s Ibrutinib in WM

https://pharmaphorum.com/news/beigenes-brukinsa-fails-to-beat-abbvie-jjs-ibrutinib-in-wm/

News/ News/ Oncology

ASH19: AZ’s Calquence throws gauntlet down to Imbruvica

Phil Taylor AbbVie, AstraZeneca, Calquence, chronic lymphocytic leukaemia, Haematology, Imbruvica, Johnson & Johnson 0 Comment

AstraZeneca’s resurgent cancer division could have another winner on its hands. Stellar data with newly-approved BTK inhibitor Calquence

ASH19: AZ’s Calquence throws gauntlet down to Imbruvica

https://pharmaphorum.com/news/ash19-azs-calquence-throws-gauntlet-down-to-imbruvica/

Market Access/ News/ News

FDA nod for AZ’s Calquence sets up new Imbruvica showdown

Phil Taylor AbbVie, AstraZeneca, BeiGene, Brukinsa, BTK inhibitor, Calquence, chronic lymphocytic leukaemia, Imbruvica, Johnson & Johnson 0 Comment

AbbVie and Johnson & Johnson are facing a challenge to their blockbuster chronic lymphocytic leukaemia drug Imbruvica from

FDA nod for AZ’s Calquence sets up new Imbruvica showdown

https://pharmaphorum.com/news/fda-nod-for-azs-calquence-sets-up-new-imbruvica-showdown/

News/ News/ R&D

AbbVie and J&J claim new Imbruvica okay in US

Phil Taylor AbbVie, CLL, Imbruvica, Johnson & Johnson 0 Comment

AbbVie and Johnson & Johnson’s Imbruvica has become the first chemo-free treatment for first-line chronic lymphocytic leukaemia (CLL)

AbbVie and J&J claim new Imbruvica okay in US

https://pharmaphorum.com/news/abbvie-and-jj-claim-new-imbruvica-okay-in-us/

News/ News/ R&D

AbbVie and J&J’s Imbruvica fails pancreatic cancer test

Phil Taylor AbbVie, Imbruvica, Johnson & Johnson 0 Comment

AbbVie and Johnson & Johnson’s hopes of adding pancreatic cancer to the repertoire of oncology blockbuster Imbruvica has

AbbVie and J&J’s Imbruvica fails pancreatic cancer test

https://pharmaphorum.com/news/abbvie-and-jjs-imbruvica-fails-pancreatic-cancer-test/

Trending

Imbruvica

Login